Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
View Patent ↗This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
1. A viral vector comprising a gene expression modulation system comprising:
a) a first gene expression cassette that is capable of being expressed in a host cell, comprising a polynucleotide that encodes a first hybrid polypeptide comprising a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and
b) a second gene expression cassette that is capable of being expressed in the host cell comprising a polynucleotide that encodes a second hybrid polypeptide comprising a transactivation domain,
wherein said first hybrid polypeptide or said second hybrid polypeptide further comprises an ecdysone receptor ligand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 43, and SEQ ID NO: 59, and
wherein said first hybrid polypeptide or said second hybrid polypeptide that does not comprise said ecdysone receptor ligand binding domain further comprises a retinoid X receptor ligand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32.
2. The viral vector according to claim 1 , said gene expression modulation system further comprising a third gene expression cassette comprising:
i) a response element recognized by the DNA-binding domain of the first hybrid polypeptide;
ii) a promoter that is activated by the transactivation domain of the second hybrid polypeptide; and
iii) a gene whose expression is to be modulated.
3. The viral vector according to claim 1 , wherein the ecdysone receptor ligand binding domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 53, and SEQ ID NO: 45.
4. The viral vector according to claim 1 , wherein the retinoid X receptor ligand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
5. The viral vector according to claim 1 , wherein the DNA-binding domain is selected from the group consisting of a GAL4 DNA-binding domain, a LexA DNA-binding domain, and an ecdysone receptor ligand binding domain.
6. The viral vector according to claim 1 , wherein the transactivation domain is selected from the group consisting of a VP16 transactivation domain, a B42 acidic activator transactivation domain, and a retinoid X receptor ligand binding domain from an invertebrate species.
7. The viral vector according to claim 1 , wherein:
a) said first hybrid polypeptide comprises:
i) said DNA-binding domain; and
ii) said ecdysone receptor ligand binding domain; and
b) said second hybrid polypeptide comprises:
i) said transactivation domain; and
ii) said retinoid X receptor ligand binding domain.
8. The viral vector according to claim 7 , further comprising, a third gene expression cassette comprising:
i) a response element recognized by said DNA-binding domain;
ii) a promoter that is activated by said transactivation domain; and
iii) a gene whose expression is to be modulated.
9. The viral vector according to claim 7 , wherein the retinoid X receptor ligand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
10. The viral vector according to claim 7 , wherein the ecdysone receptor ligand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 53 and SEQ ID NO: 45.
11. The viral vector according to claim 7 , wherein the DNA-binding domain is selected from the group consisting of a GAL4 DNA-binding domain, a LexA DNA-binding domain, and a retinoid X receptor ligand binding domain from an invertebrate species.
12. The viral vector according to claim 7 , wherein the transactivation domain is selected from the group consisting of a VP16 transactivation domain, a B42 acidic activator transactivation domain, and an ecdysone receptor ligand binding domain.
13. An isolated host cell comprising the viral vector according to claim 1 .
14. The isolated host cell according to claim 13 , wherein the host cell is selected from the group consisting of a bacterial cell, a fungal cell, a yeast cell, an animal cell, and a mammalian cell.
15. The isolated host cell according to claim 14 , wherein the mammalian cell is a murine cell or a human cell.
16. An isolated host cell comprising the viral vector according to claim 7 .
17. The isolated host cell according to claim 16 , wherein the host cell is selected from the group consisting of a bacterial cell, a fungal cell, a yeast cell, an animal cell, and a mammalian cell.
18. The isolated host cell according to claim 17 , wherein the mammalian cell is a murine cell or a human cell.
19. The viral vector of claim 1 , wherein said gene expression modulation system exhibits increased ligand sensitivity, relative to the ligand sensitivity of a gene expression modulation system that contains a retinoid X receptor ligand binding domain from a vertebrate species.
20. The viral vector of claim 19 , wherein said gene expression modulation system exhibits increased sensitivity to non-steroidal ligands.
21. The viral vector of claim 20 , wherein said gene expression modulation system exhibits increased sensitivity to non-steroidal ligands in mammalian cells.
22. The viral vector of claim 7 , wherein said gene expression modulation system exhibits increased ligand sensitivity, relative to the ligand sensitivity of a gene expression modulation system that contains a retinoid X receptor ligand binding domain from a vertebrate species.
23. The viral vector of claim 22 , wherein said system exhibits increased sensitivity to non-steroidal ligands.
24. The viral vector of claim 23 , wherein said system exhibits increased sensitivity to non-steroidal ligands in mammalian cells.
25. The vital vector of claim 1 , wherein said vector is an adenovirus vector.
26. The viral vector of claim 7 , wherein said viral vector is an adenovirus vector.
27. The viral vector of claim 1 , wherein said gene expression, modulation system is isolated.